Revenue
2020
2021
2022
2023
2024
2025
Humacyte, Inc. (HUMA)
Price$0.6049Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | $0 | $0 | $1.6M | $1.3M | $1.5M |
| Gross profit | −$7.7M | $0 | — | — | — | — |
| Gross margin | −376.05% | — | — | — | — | — |
| Research & development | $69.3M | $88.6M | $76.5M | $63.3M | $61.3M | $54.1M |
| Operating expenses | $110.2M | $114.4M | $100.0M | $86.1M | $82.5M | $66.1M |
| Operating income | −$108.1M | −$114.4M | −$100.0M | −$84.6M | −$81.2M | −$64.6M |
| Operating margin | −5,306.04% | — | — | −5,404.35% | −6,429.77% | −4,332.66% |
| EBITDA | −$100.8M | −$107.2M | −$92.3M | −$76.4M | −$73.0M | −$56.2M |
| EBITDA margin | −4,945.63% | — | — | −4,879.74% | −5,777.28% | −3,772.57% |
| Net income | −$40.8M | −$148.7M | −$110.8M | −$12.0M | −$26.5M | −$66.5M |
| Net profit margin | −2,003.58% | — | — | −764.54% | −2,096.36% | −4,461.70% |
| Basic EPSper basic share | -$0.26 | -$1.26 | -$1.07 | -$0.12 | -$0.66 | -$11.54 |
| Diluted EPSper diluted share | -$0.26 | -$1.26 | -$1.07 | -$0.12 | -$0.66 | -$11.54 |
Owners
Reported shareholders
3.64%of listed shares
VANGUARD CAPITAL MANAGEMENT LLC10.11M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
VANGUARD CAPITAL MANAGEMENT LLC | 3.64%10.11M shares |
ANTIPODES PARTNERS Ltd | 3.64%10.1M shares |
Alyeska Investment Group, L.P. | 2.17%6.02M shares |
Davidson Kempner Capital Management LP | 1.80%5M shares |
BlackRock, Inc. | 1.74%4.84M shares |
GREAT POINT PARTNERS LLC | 1.35%3.75M shares |
UBS Group AG | 1.02%2.84M shares |
AQR CAPITAL MANAGEMENT LLC | 0.93%2.6M shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.79%2.19M shares |
MILLENNIUM MANAGEMENT LLC | 0.69%1.91M shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.61%1.7M shares |
CITADEL ADVISORS LLC | 0.52%1.44M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.49%1.35M shares |
VANGUARD FIDUCIARY TRUST CO | 0.43%1.18M shares |
HRT FINANCIAL LP | 0.39%1.09M shares |
LPL Financial LLC | 0.37%1.03M shares |
GSA CAPITAL PARTNERS LLP | 0.36%1.01M shares |
Private Advisor Group, LLC | 0.35%965.09K shares |
STATE STREET CORP | 0.30%842.54K shares |
HBK INVESTMENTS L P | 0.28%790K shares |
Percentages use 277.8M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 19, 2026Form 4 | Sebelius KathleenDirector | BuyCommon Stock | 56.8K | $0.88 | $50.0K | 148.0K |
| May 18, 2026Form 4 · 10b5-1 | Parikh Shamik JChief Medical Officer | SellCommon Stock | 45.9K | $0.90 | $41.3K | 272.7K |
| May 18, 2026Form 4 · 10b5-1 | Sander Dale A.CFO and Chief Corp. Dev. Off | SellCommon Stock | 45.9K | $0.90 | $41.3K | 267.2K |
| May 18, 2026Form 4 | Constantino Michael T.Director | BuyCommon Stock | 11.0K | $0.89 | $9.8K | 44.0K |
| Aug 20, 2025Form 4 | Dougan Brady WDirector | SellCommon Stock · indirect | 591.7K | $1.58 | $934.9K | 0 |